Graybug Vision – Flush with Cash – Is Making Big Moves to Change its Approach to Finding New Treatments for Wet AMD & Other Eye Disease
Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker.
Activity